NASDAQ · CYAD
Healthcare · Biotechnology
$0.47
Down-$0.07 (-12.96%)
Updated Aug 24, 2026, 3:41 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CYAD does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CYAD.
CYAD research
Company profile and research snapshot.
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 11, 2022 | Wells Fargo | Overweight | — |
| Aug 6, 2021 | HC Wainwright & Co. | Buy | — |
| May 10, 2021 | HC Wainwright & Co. | Buy | — |
| Mar 26, 2021 | JonesTrading | Hold | — |
| Dec 8, 2020 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · May 15, 2023
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies.
GlobeNewswire Inc. · May 5, 2023
MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today reports its financial results for the first quarter of 2023 and provides an update on recent business developments.
GlobeNewswire Inc. · May 5, 2023
MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that its Board of Directors has approved the voluntary delisting of its American Depositary Shares representing ordinary shares (“ADSs”) from the Nasdaq Global Market, termination of its American Depositary Receipt (“ADR”) facility and deregistration with the U.S. Securities and Exchange Commission (the “SEC”) upon satisfaction of the requirements for deregistration. The Company will continue to be listed on Euronext Brussels.
GlobeNewswire Inc. · Apr 24, 2023
MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Bid Price Notice”) on April 19th, 2023 from The Nasdaq Stock Market (“Nasdaq”) informing the Company that the minimum closing bid price per share of its American Depositary Shares representing ordinary shares (“ADSs”) was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CYAD.
No results
No recent SID articles mention CYAD.
